Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2023 Dec 15;18(12):e0295175. doi: 10.1371/journal.pone.0295175

Effects of a mindfulness-based intervention and a health self-management programme on psychological well-being in older adults with subjective cognitive decline: Secondary analyses from the SCD-Well randomised clinical trial

Marco Schlosser 1,2, Harriet Demnitz-King 2, Thorsten Barnhofer 3, Fabienne Collette 4,5, Julie Gonneaud 6, Gaël Chételat 6, Frank Jessen 7,8,9, Matthias Kliegel 1, Olga M Klimecki 10,11, Antoine Lutz 12,‡,*, Natalie L Marchant 2,‡,*; on behalf of the Medit-Ageing Research Group
Editor: Marcelo Marcos Piva Demarzo13
PMCID: PMC10723715  PMID: 38100477

Abstract

Objectives

Older adults with subjective cognitive decline (SCD) recruited from memory clinics have an increased risk of developing dementia and regularly experience reduced psychological well-being related to memory concerns and fear of dementia. Research on improving well-being in SCD is limited and lacks non-pharmacological approaches. We investigated whether mindfulness-based and health education interventions can enhance well-being in SCD.

Methods

The SCD-Well trial (ClinicalTrials.gov: NCT03005652) randomised 147 older adults with SCD to an 8-week caring mindfulness-based approach for seniors (CMBAS) or an active comparator (health self-management programme [HSMP]). Well-being was assessed at baseline, post-intervention, and 6-month post-randomisation using the Psychological Well-being Scale (PWBS), the World Health Organisation’s Quality of Life (QoL) Assessment psychological subscale, and composites capturing meditation-based well-being dimensions of awareness, connection, and insight. Mixed effects models were used to assess between- and within-group differences in change.

Results

CMBAS was superior to HSMP on changes in connection at post-intervention. Within both groups, PWBS total scores, psychological QoL, and composite scores did not increase. Exploratory analyses indicated increases in PWBS autonomy at post-intervention in both groups.

Conclusion

Two non-pharmacological interventions were associated with only limited effects on psychological well-being in SCD. Longer intervention studies with waitlist/retest control groups are needed to assess if our findings reflect intervention brevity and/or minimal base rate changes in well-being.

Introduction

Subjective cognitive decline (SCD) describes self-reported worsening of cognitive functioning despite unimpaired performance on objective tests of cognition [1]. Clinical and epidemiological data suggest that older adults with SCD, especially those recruited from memory clinics, are at a higher risk of subsequently developing dementia [2]. The aetiology of SCD is heterogeneous and its phenomenology complex [1]. Although the condition could be an indication of prodromal Alzheimer’s disease (AD), which is the most common form of dementia [3], SCD has also been related to other factors (e.g., physical and mental illness, sleep disturbances, personality traits, effects of drugs). Partly due to the heterogeneity of this population and the fact that SCD symptoms frequently remit, there is no consensus on best treatment and management for SCD. Nonetheless, in the absence of effective interventions for curing or treating AD, interest in SCD continues to grow as targeted interventions at this earlier stage could reduce the risk of cognitive decline and progression to AD.

An important aspect of living with SCD is the impact that perceiving increasing cognitive difficulties has on an individual’s psychological well-being. The lived subjective experience of individuals with SCD is commonly marked by stress, fear of dementia, anger, and feelings of anxiety and depression [4, 5]. This aspect can be overlooked within research contexts that focus primarily on the maintenance of cognition or the prevention of amyloid deposition. A recent meta-analysis indicated that group psychological interventions moderately increased psychological well-being in SCD (Hedges’ g = 0.40; [6]) although none of the included studies, when considered individually, found statistically significant improvements. The authors concluded that existing research on enhancing psychological well-being in SCD is of low quality (e.g., lacking active comparison conditions) and highlighted the striking lack of research on non-pharmacological approaches including lifestyle and mindfulness-based interventions (MBIs).

In line with prior research and theory [7, 8], MBIs have been proposed as a promising strategy for increasing psychological well-being and human flourishing. However, prior to the SCD-Well trial [9], only one study–a small pilot randomised controlled trial (n = 15; [10])–had evaluated the effects of mindfulness training in individuals with SCD. This trial primarily focussed on reaction time and EEG/ERP correlates, change in brain volume, self-reported cognitive complaints, and memory self-efficacy; it did not include measures of psychological well-being or related constructs. Understanding how psychological well-being in SCD, irrespective of its aetiology, could be improved through MBIs remains an important lacuna in this emerging field.

Other promising non-pharmacological interventions for SCD include psychoeducation programmes that provide information on healthy diet, physical exercise, and management of existing health conditions [1]. Strengthening self-efficacy and thus enabling individuals with SCD to live a more active life could be a mechanism by which psychoeducation maintains or improves psychological well-being. A particularly pertinent feature of both MBIs and psychoeducation is their potential to be feasibly implemented in clinical settings. Furthermore, non-pharmacological interventions could empower individuals with SCD to actively learn skills that could enhance their psychological well-being and mental health instead of passively observing how their clinical trajectory unfolds.

Research on the dimensions of psychological well-being has expanded substantially over the past decade, delivering valuable insights into the conditions that predict and contribute to positive functioning (e.g., [7, 11]). To appreciate the conceptual richness of this field and to capture diverse aspects of psychological well-being, we utilised outcome measures derived from three distinct, prominent theoretical models of human flourishing, namely Ryff’s theory of well-being [12], the World Health Organisation’s conception of psychological quality of life [13], and a recent meditation training-based framework for human flourishing developed by Dahl et al. [7].

Ryff [12] offered the first attempt at providing a unifying theoretical framework for contemporary scientific perspectives on human flourishing. Ryff’s influential work was a response to the largely data-driven and atheoretical research on well-being that had hitherto characterised this area. In this model, Ryff aimed to identify the fundamental aspects of positive functioning that could help define what it means to be psychologically well. The Psychological Well-being Scale (PWBS; [14]), which was developed to empirically capture Ryff’s proposed dimensions of well-being, is the most cited self-report measure of well-being to date.

The World Health Organisation (WHO) defines quality of life as “individuals’ perceptions of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns” [13] and frames quality of life as an aspect of well-being. The WHO Quality of Life (WHOQOL) assessment was developed to capture aspects of quality of life. The introduction of the WHOQOL was a statement of commitment to promoting a genuinely holistic approach to health and health care interventions, echoing the WHO’s definition of health as “A state of physical, mental and social well-being, not merely the absence of disease and infirmity” [13].

Dahl et al.’s [7] meditation training-based model of human flourishing integrates insights from neuroscientific and psychological research on well-being with contemplative perspectives. It rests on a skill-based conception of human flourishing, framing dimensions of well-being as trainable capacities. The authors aimed to introduce a set of constructs that could further unify existing theories and interventions in this field while offering a common language to encourage collaboration across related research areas. No self-report measure has yet been developed that was explicitly derived from this model. However, recent research [15] has used this model to group already published self-report measures into psychometrically sound composites of meditation-based well-being.

The present study aimed to compare the effects of an 8-week MBI adapted for older adults with SCD (caring mindfulness-based approach for seniors; CMBAS) on measures of mental well-being derived from the three approaches described above to a structurally matched health self-management programme (HSMP). We hypothesised that both interventions would improve well-being but that CMBAS would be superior to HSMP, because, based on previous research and theory [7, 16, 17], we predicted embodied meditative practices aimed at deep human flourishing to be a more potent catalyst of well-being than health educational instructions.

Methods

This study utilised longitudinal data from the SCD-Well randomised controlled trial of the European Union’s Horizon 2020-funded Medit-Ageing European project (public name: Silver Santé Study). Detailed information about the recruitment procedures, eligibility criteria, design of the interventions, and assessments can be found in the trial protocol [18].

Study design

SCD-Well was a multi-center, randomized, controlled, superiority trial with two intervention arms: an 8-week CMBAS and a structurally matched HSMP. Randomisation to one of the two groups was performed at a ratio of 1:1. Participants were assessed at three visits: pre-intervention at baseline (V1), post-intervention (V2), and at follow-up 6 months after randomisation (V3). The primary outcome of the SCD-Well trial was mean change in anxiety symptoms from V1 to V2 [9].

The intervention was delivered at four European sites (Barcelona, Cologne, London, and Lyon). Written informed consent was obtained from all participants after the procedures had been explained to them and prior to participation. The multi-centre SCD-Well trial received ethics approval from the committees and regulatory agencies of all centres: London, UK (Queen Square Research Ethics Committee: n° 17/LO/0056 and Health Research Authority National Health Service, IRAS project ID: 213008); Lyon, France (Comité de Protection des Personnes Sud-Est II Groupement Hospitalier Est: n° 2016-30-1 and Agence Nationale de Sécurité du Médicament et des Produits de Santé: IDRCB 2016-A01298-43); Cologne, Germany (Ethikkommission der Medizinischen Fakultät der Universität zu Köln: n° 17–059); and Barcelona, Spain (Comité Etico de Investigacion Clinica del Hospital Clinic de Barcelona: n° HCB/2017/0062). The SCD-Well trial was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Participants

A total of 147 older adults (age range: 60 to 91 years in CMBAS; 60 to 87 years in HSMP) were randomised. Participants had no major neurological or psychiatric disorders, and no present or past regular or intensive practice of meditation, were recruited from memory clinics at four European sites, and met the research criteria for SCD proposed by the SCD-I working group [19].

Interventions

Caring mindfulness-based approach for seniors (CMBAS)

CMBAS followed the structure of a mindfulness-based stress reduction (MBSR) programme and was tailored to the needs of older adults with a focus on compassion and loving-kindness meditation. CMBAS also included psychoeducational components that offered participants approaches to deal with cognitive concerns and tendencies to worry in skilful ways. The intervention consisted of eight weekly group sessions of approximately 2 hours, home practice (e.g., guided meditations, informal practices) for 1 hour per day on six days per week, and one retreat day during the sixth week of the intervention that involved 5 hours of practice. CMBAS was delivered to groups of 7 to 12 participants by clinically trained facilitators who had completed training that aligned with the good practice guidelines for mindfulness teachers developed by The Mindfulness Network UK.

Health self-management programme (HSMP)

HSMP followed the same format and structure as CMBAS, and was matched in administration, duration, and dosage of group meetings including a retreat day with a healthy lunch and topical discussions. HSMP was based on a published manual that included guidance on exercise, stress, memory, communication, healthy eating, and the management of sleep [20]. Home practice included creating ‘action plans’ that focussed on activities to enhance health and well-being. HSMP was delivered to groups of 7 to 13 participants by clinically trained facilitators with at least three years of experience in leading group-based clinical or psychoeducational interventions.

Measures of well-being

The 42-item Psychological Well-being Scale (PWBS; [14]) was used to measure psychological well-being as conceptualised by Ryff [12]. The PWBS is grounded in a theoretical model of psychological well-being that comprises six dimensions, namely self-acceptance, positive relations with others, autonomy (independence), environmental mastery (ability to manage life’s demands), purpose in life, and personal growth (sense of developing and growing; [12]). Each dimension is measured by a 7-item subscale using a 7-point Likert scale ranging from 1 (strongly agree) to 7 (strongly disagree). After reverse scoring 21 items, subscale scores were derived by averaging their respective item scores; a total score was derived by averaging all items. Higher scores reflect higher levels of psychological well-being. The subscales of the PWBS have displayed low to moderate levels of internal consistency (Cronbach’s alpha ranging from 0.33 to 0.56; [14]).

The psychological domain of the World Health Organization WHOQOL-BREF Quality of Life Assessment [13] was used to measure psychological quality of life. The WHOQOL Group conceptualises quality of life as a subjective evaluation of one’s position in life in relation to the goals, expectations, and concerns that emerge from one’s cultural, social, and environmental context. The psychological subscale of the WHOQOL-BREF captures levels of positive feelings (e.g., sense of meaningfulness) and body image, self-esteem, the ability to concentrate, and the lack of negative feelings (e.g., anxiety). The 6-item psychological subscale uses a 5-point Likert scale anchored at 0 (not at all) and 5 (completely). After reverse scoring one item, psychological subscale scores were derived by summing the six item scores. Higher scores are indicative of higher levels of psychological quality of life. The psychological subscale of the WHOQOL-BREF has displayed good levels of internal consistency (Cronbach’s alpha = 0.81; [13]).

Three composite scores were used to measure the meditation-related well-being dimensions of awareness, connection, and insight as introduced by Dahl et al. [7]. In this framework, awareness describes a heightened and malleable attentiveness to perceptions (e.g., thoughts, feelings, and sensations) and a capacity to notice when levels of awareness decrease and the likelihood to be distracted increases. Connection describes a sense of care toward others that supports positive interactions and relationships. Connection encompasses feelings of gratitude, appreciation, and kinship, and a heightened capacity to understand and empathise with others’ perspectives. Insight describes the capacity to experientially understand the ways in which thoughts, feelings, assumptions, and worldviews shape and participate in one’s perception of self, other, and world. Awareness, connection, and insight correspond to the attentional, constructive, and deconstructive psychological capacities previously introduced by Dahl et al. [16]. Details of the theory-guided development and psychometric properties of the composites used in the present study have been published [15]. The three composite scores include scales or subscales from four self-report measures (see Table 2): The Multidimensional Assessment of Interoceptive Awareness (MAIA; [21]) questionnaire and the 39-item Five Facet Mindfulness Questionnaire (FFMQ-39; [22]) subscales of observing (noticing experiences) and acting with awareness (attending to activities non-mechanically) were used as measures of awareness. The Compassionate Love Scale (stranger-humanity version; [23, 24]) was used as a measure of connection. The Drexel Defusion Scale [25] and the FFMQ subscales of non-judging (non-evaluative stance towards experiences) and non-reactivity (allowing experiences) were used as measures of insight. Detailed descriptions of the self-report measures included in the composite scores can be found in S1 Table in S1 File.

Table 2. Descriptive statistics for well-being outcomes by group and visit based on all available data.
CMBAS HSMP
V1 V2 V3 V1 V2 V3
Outcome n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
PWBS
    Total 72 4.5 (1.2) 59 4.4 (1.3) 58 4.5 (1.2) 70 4.5 (1.2) 56 4.6 (1.3) 63 4.6 (1.2)
    Autonomy 71 4.7 (1) 59 4.9 (1) 59 4.8 (0.9) 70 4.9 (0.9) 56 5.1 (0.9) 63 5.1 (0.9)
    Environmental mastery 72 4.6 (1.5) 59 4.5 (1.7) 59 4.6 (1.6) 70 4.5 (1.5) 57 4.5 (1.6) 63 4.6 (1.5)
    Personal growth 72 4.4 (1.3) 59 4.3 (1.3) 58 4.3 (1.3) 70 4.3 (1.3) 56 4.4 (1.4) 63 4.3 (1.3)
    Positive relations 71 4.7 (1.5) 59 4.5 (1.6) 59 4.5 (1.6) 70 4.8 (1.5) 56 4.8 (1.6) 63 4.8 (1.5)
    Purpose in life 72 4.3 (1.4) 59 4.2 (1.5) 58 4.3 (1.4) 70 4.2 (1.4) 56 4.2 (1.4) 63 4.3 (1.4)
    Self-acceptance 72 4.4 (1.4) 59 4.3 (1.5) 59 4.4 (1.4) 70 4.5 (1.5) 56 4.5 (1.5) 63 4.5 (1.5)
Psychological QoL 71 21.6 (3.8) 59 22.3 (3.8) 59 22.2 (4.7) 69 22.3 (3.1) 58 22.7 (3.5) 62 22.9 (3.4)
Awareness
    MAIA noticing 72 3.0 (1.2) 59 3.1 (1.2) 59 3.2 (1.2) 69 2.8 (1.2) 58 3.1 (1.2) 61 2.9 (1.3)
    MAIA attention regulation 71 2.6 (1.1) 59 2.8 (1.0) 59 2.7 (0.9) 67 2.8 (0.9) 56 2.8 (0.9) 62 2.9 (0.8)
    MAIA emotional awareness 72 3.3 (1.1) 59 3.3 (1.1) 59 3.3 (1.1) 67 3.5 (1.0) 58 3.4 (1.1) 62 3.4 (1.1)
    MAIA self-regulation 71 2.4 (1.1) 59 3.0 (1.1) 59 3.0 (1.0) 66 2.7 (1.0) 57 2.9 (1.0) 62 2.8 (1.0)
    MAIA body listening 71 1.8 (1.2) 59 2.4 (1.0) 58 2.3 (1.0) 69 1.9 (1.2) 58 2.1 (1.2) 62 2.2 (1.1)
    FFMQ observing 72 9.6 (2.6) 59 9.3 (2.2) 60 9.2 (2.6) 70 9.5 (2.7) 58 9.6 (2.7) 62 9.6 (2.8)
    FFMQ act with awareness 72 10.3 (3.0) 59 10.2 (3.1) 59 10.0 (3.0) 70 10.6 (2.6) 58 10.5 (2.9) 62 11.0 (2.9)
Connection
    Compassionate Love Scale 71 89.5 (22.1) 58 89.2 (21.5) 59 86.9 (23.1) 70 95.2 (18.1) 58 92.2 (24.7) 62 90.0 (22.5)
Insight
    Drexel Defusion Scale 71 30.1 (8.3) 59 31.7 (9.7) 60 32.7 (8.3) 69 33.4 (8.4) 58 34.6 (6.7) 62 34.2 (7.0)
    FFMQ non-judging 72 11.8 (2.8) 59 12.1 (2.6) 60 11.7 (3.0) 70 11.8 (2.5) 58 12.1 (2.6) 62 11.7 (3.0)
    FFMQ non-reactivity 72 9.6 (2.9) 59 9.4 (3.1) 59 9.6 (2.5) 70 9.3 (3) 58 9.1 (2.9) 62 9.0 (2.8)

Note. PWBS = Psychological Well-being Scale; QoL = Quality of Life; SD = standard deviation; CMBAS = Caring Mindfulness-based Approach for Seniors; HSMP = Health Self-Management Programme; PWBS = Psychological Well-being Scale; QoL = quality of life; MAIA = Multidimensional Assessment of Interoceptive awareness; FFMQ = Five Facet Mindfulness Questionnaire.

To derive the three scores of meditation-related dimensions of well-being, we subtracted each scale score at each time point from the baseline pooled mean. We then divided this difference by the baseline pooled standard deviation. Next, each score was computed by averaging the z-scores of the scales that were assigned to the respective composite, yielding three composite scores with a baseline mean of 0 and a standard deviation smaller than one. Finally, to ease longitudinal data interpretation, we re-standardised each composite score so that longitudinal changes in each composite score reflect changes in standard deviation units.

Statistical analyses

Sample size

Sample size calculations in SCD-Well were based on the expected effect size (0.5, based on a meta-analysis of the efficacy of meditation-based interventions for reducing anxiety symptoms; [26]) with 80% power and two-sided type I error of 5% for the mean change in trait-STAI scores from V1 to V2 between CMBAS and HSMP, resulting in a minimum total number of 128 (64 per group), which has been exceeded (n = 147; detailed in [18].

Comparative analyses

To assess between-group differences in mean changes in outcomes, we built one mixed effects linear regression model for each outcome incorporating data from all time points with an interaction term between visit and group. In all analyses, positive (negative) estimated mean between-group differences reflect higher (lower) changes in outcome scores in CMBAS. In accordance with the pre-registered statistical analysis plan for secondary outcomes of the Medit-Ageing Project, in all mixed effects regression models, missing data of the well-being outcomes were not replaced and assumed to be missing-at-random. The data and analysis plan underlying this paper are made available on request following approval by the executive committee and a formal data sharing agreement (https://silversantestudy.eu/2020/09/25/data-sharing). No participant data were excluded based on very high or low scale scores. Primary analyses of PWBS total scores, psychological QoL, and composite scores (awareness, connection, insight) were adjusted for multiple comparison (Bonferroni correction for multiple testing). Exploratory analyses of PWBS subscales were not adjusted for multiple comparison.

To test the potential moderating effect on measures of well-being within both groups, we built linear regression models with change in well-being scores from V1 to V2 as the outcome and the moderator variables of interest as the predictors. These variables included session attendance (out of a maximum of nine sessions, i.e. 8 weekly meetings plus one retreat day), baseline neuroticism measured by the neuroticism subscale of the 44-item Big Five Inventory [27], and baseline scores of the well-being outcomes. Analyses were conducted in R version 4.0.2 and Stata/MP version 16.0.

Results

Demographic characteristics are reported in Table 1. Descriptive statistics of well-being outcomes (based on all available data) are displayed in Table 2 and Fig 1. Results from mixed effects regression models assessing differential change in well-being outcomes (based on all participants who provided data at V1, V2, and V3) are shown in Table 3. There were no significant differences between the interventions for the mean number of sessions attended (CMBAS = 6.7; HSMP = 6.8), the proportion of participants who attended at least four sessions (CMBAS = 81%; HSMP = 85%), or the proportion of participants who reported continued engagement with intervention activities between V2 and V3 (CMBAS = 59%; HSMP = 54%). There were no significant differences between the proportions of participants who completed home practice on at least four occasions (CMBAS = 55 [75%]; HSMP = 51 [69%]).

Table 1. Baseline demographic characteristics.

CMBAS (n = 73) HSMP (n = 74)
Age, in years 72.1 (7.5) 73.2 (6.2)
Female, n (%) 47 (64.4%) 48 (64.9%)
Education, in years 13.9 (3.8) 13.4 (3.4)
Ethnicity (white), n (%) 69 (95%) 72 (99%)

Note. All variables are mean (standard deviation) unless otherwise specified. CMBAS = Caring Mindfulness-based Approach for Seniors; HSMP = Health Self-Management Programme.

Fig 1. Longitudinal changes in meditation-based well-being composite scores (awareness, connection, insight), Psychological Well-being Scale (PWBS) total scores, and WHOQOL-BREF Psychological Quality of Life (QoL) by group (CMBAS = Caring Mindfulness-based Approach for Seniors, HSMP = Health Self-Management Programme).

Fig 1

The figure displays observed standardised means and SEs (error bars = 1 SE) based on all available data.

Table 3. Results from mixed effects models assessing differential change in well-being outcomes.

Standardised estimated change Difference in change
CMBAS vs. HSMP
Outcome Time CMBAS HSMP Mean (95% CI) p
PWBS total V1 to V2 0.02 (-0.11, 0.14) 0.05 (-0.07, 0.17) 0.03 (-0.11, 0.18) 0.638
V1 to V3 0.01 (-0.12, 0.13) 0.09 (-0.03, 0.21) 0.08 (-0.06, 0.23) 0.253
Psychological QoL V1 to V2 0.18 (-0.06, 0.43) 0.04 (-0.21, 0.29) 0.14 (-0.15, 0.44) 0.337
V1 to V3 0.09 (-0.35, 0.17) 0.10 (-0.15, 0.34) -0.002 (-0.29, 0.29) 0.990
Awareness V1 to V2 0.17 (-0.07, 0.40) 0.10 (-0.15, 0.35) 0.08 (-0.22, 0.36) 0.628
V1 to V3 0.05 (-0.19, 0.29) 0.14 (-0.10, 0.38) -0.08 (-0.37, 0.20) 0.556
Connection V1 to V2 0.20 (-0.02, 0.42) -0.18 (-0.40, 0.04) 0.38 (0.12, 0.64) 0.004
V1 to V3 -0.01 (-0.22, 0.21) -0.31 (-0.53, -0.10) 0.30 (0.05, 0.56) 0.020
Insight V1 to V2 0.12 (-0.10, 0.35) 0.02 (-0.21, 0.25) 0.10 (-0.16, 0.37) 0.454
V1 to V3 0.10 (-0.12, 0.33) -0.04 (-0.26, 0.18) 0.14 (-0.12, 0.41) 0.284

Note. Only participants who provided data at all three time points were included in the analyses. All analyses were adjusted for baseline scores of the outcome. Estimates in bold were associated p < 0.005 (significance threshold adjusted using the Bonferroni correction for multiple testing). PWBS = Psychological Well-being Scale; QoL = Quality of Life; SCD = subjective cognitive decline; CI = confidence interval; CMBAS = Caring Mindfulness-based Approach for Seniors; HSMP = Health Self-Management Programme.

PWBS

CMBAS and HSMP did not increase PWBS total scores, and no differences were observed between CMBAS and HSMP on changes in PWBS total scores (Table 3).

Exploratory analyses indicated that across PWBS dimensions, only PWBS autonomy increased within both groups from V1 to V2 (CMBAS: Cohen’s d: 0.22 [95% CI: 0.02, 0.42], p = 0.023; HSMP: Cohen’s d: 0.24 [95% CI: 0.03, 0.44], p = 0.018) and from V1 to V3 in HSMP only (Cohen’s d: 0.22 [95% CI: 0.02, 0.41], p = 0.026; S2 Table in S1 File). Neither CMBAS nor HSMP increased other PWBS dimensions from V1 to V2 or from V1 to V3.

Psychological QoL

No differences were observed between CMBAS and HSMP on changes in psychological QoL from V1 to V2 (Cohen’s d: 0.15 [95% CI: -0.08, 0.37], p = 0.206) and from V1 to V3 (Cohen’s d: 0.15 [95% CI: -0.08, 0.37], p = 0.206). No within-group changes were found.

Meditation-based well-being dimensions

CMBAS was superior to HSMP on changes in connection from V1 to V2 (Cohen’s d: 0.38 [95% CI: 0.12, 0.64], p = 0.004). From V1 to V2, connection did not change within CMBAS (Cohen’s d: 0.20 [95% CI: -0.02, 0.42], p = 0.082) or within HSMP (Cohen’s d: -0.18 [95% CI: -0.40, 0.04], p = 0.132). From V1 to V3, a significant decrease in connection was observed within HSMP (Cohen’s d: -0.31 [95% CI: -0.53, -0.10], p = 0.002). No differences were observed between CMBAS and HSMP on changes in awareness and insight (all p-values > 0.284), and no within-group changes were observed for these outcomes.

Moderator analyses

Exploratory moderator analyses were conducted within both groups to assess the association between baseline characteristics and intervention response (i.e., from V1 to V2). For a selected number of outcomes (CMBAS: awareness, connection, insight, psychological QoL; HSMP: insight), higher baseline scores were associated with weaker improvements. Neuroticism did not moderate the effects of CMBAS or HSMP. Session attendance showed a moderating effect on connection, with higher session attendance predicting a greater decrease in connection in CMBAS and a greater increase in connection in HSMP. All moderator analyses can be found in S3 Table in S1 File.

Discussion

Utilising three theory-based conceptions of well-being [7, 12, 13] in this large, multinational clinical trial of older adults with SCD, an 8-week CMBAS and a structurally matched HSMP were associated with only limited effects on psychological well-being. CMBAS was superior to HSMP on changes in connection at post-intervention. Within both groups, PWBS total scores, psychological QoL, and composite scores did not increase significantly from baseline to post-intervention or follow-up. Exploratory analyses suggested that levels of autonomy increased within both groups during the intervention. In Ryff’s framework of well-being [14], increasing levels of autonomy reflect an increased capacity to be independent, self-determined, and able to view oneself and regulate one’s behaviour based on personal standards rather than social and cultural pressures.

Overall, however, our findings contrast with our hypotheses. Based on previous research and theory [7, 17, 28], we expected CMBAS to positively impact various dimensions of psychological well-being and human flourishing. The primary outcome of the SCD-Well trial was mean change in levels of trait anxiety from pre- to post-intervention [18]. Within both CMBAS and HSMP, trait anxiety was reduced in statistically significant and clinically meaningful ways [9]. The magnitude of these effects on the primary outcome did not fully translate to the well-being measures presented here. Despite decreases in trait anxiety, CMBAS’ limited effects on psychological well-being raise concerns about the utility and specificity of an 8-week MBI in older adults with SCD.

Several potential explanations for these unexpected findings can be considered. For instance, one explanation relates to the limitations of the well-being measures we employed. The PWBS [14] and WHOQOL-BREF Quality of Life Assessment [13] were not informed by contemplative perspectives or developed to measure the effects of meditation training. These well-being measures might be limited in their ability to capture those dimensions of well-being that meditation theories would predict long-term practice to cultivate [7, 16]. In fact, a recent cross-sectional study suggested that expert meditators (≥10,000 hours of practice including one 3-year meditation retreat) displayed lower PWBS total scores than meditation-naïve individuals [15]. Nonetheless, from a clinical perspective, we still expected an improvement in the general type of well-being that is captured by these measures. Importantly, the present study did include composite measures that were theoretically derived from meditation-based dimensions of well-being (i.e., awareness, connection, insight; [7]). Although the impact of CMBAS on awareness and insight was arguably trending towards a meaningful effect size post-intervention, this impact was not detectable anymore at the 6-month follow-up. Another explanation for the limited effects on psychological well-being could be related to the length of the meditation training period. Although 8-week MBIs in younger healthy populations have exerted a positive impact on measures of global well-being as well as dimensions of awareness, connection, and insight (e.g., [29]), in older adults with SCD, eight weeks of practice might be too brief for measurable and clinically meaningful changes in facets of psychological well-being to manifest. Notably, in MBIs in younger healthy populations, effect sizes of change in measures of psychological distress tend to be larger than those of changes in well-being dimensions [29, 30]. This pattern also emerges in the context of the SCD-Well trial and is in line with the fact that standard MBIs, derived from the generic mindfulness-based stress reduction programme, are mainly targeted at helping participants develop more adaptive responses to psychological distress. One potential explanation for this pattern is that greater intervention duration is required for psychological well-being to improve than for psychological distress (e.g., anxiety) to decrease. In that regard, a potential lack of statistical power could have also contributed to the limited effects on well-being as the SCD-Well trial was designed to primarily detect effects on levels of trait anxiety [18]. Further, the limited intervention effects could also be related to factors that have been associated with SCD but were not sufficiently captured in the context of the present study (e.g., sleep disturbances measured by polysomnography). Longitudinal studies with longer training periods and additional measures of physical and mental health are needed to further elucidate these questions and other potential dose-response relationships between meditation practice and diverse aspects of psychological well-being in older adults. The ongoing Age-Well trial [31], which includes the longest meditation training conducted to date and utilises similar measures of well-being to the present study, could contribute to begin answering these questions.

Trajectories of change in outcomes might vary substantially depending on participants’ baseline characteristics; yet only few moderators of meditation training have been consistently found or considered [32]. Previous work has suggested that individuals who display better/poorer functioning at baseline might show a smaller/larger response to meditation-based interventions (see [33]). For individuals who are relatively psychologically well at baseline, longer training periods might be required to achieve noticeable levels of improvement. Here, we evaluated the moderating effects of baseline levels of neuroticism (i.e., proneness to experience distress) and well-being. In line with prior predictions, higher levels of awareness, connection, insight, and psychological QoL at baseline were associated with smaller improvements post-CMBAS. The opposite pattern in which higher baseline scores predicted stronger intervention response was not found for any outcome. Baseline scores of neuroticism did not predict participants’ response to CMBAS. Further, session attendance showed no moderating effects on well-being outcomes except on connection, with higher session attendance predicting, unexpectedly, a greater decrease in connection. Given the exploratory nature of these moderation analyses and the lack of prior studies investigating the effects of MBIs on well-being in patients with SCD, we hesitate to offer explanations for this counterintuitive moderation finding.

The SCD-Well trial has important strengths. Aiming to address several previously-identified limitations of meditation research [7, 33, 34], the trial included a theory-based active comparison condition; the mindfulness-based intervention was based on a tailored, manualised training paradigm that was informed by the strengths and limitations of previous work; we utilised theoretical models of meditation practice that were informed by psychological, neuroscientific, and contemplative perspectives [16]; we compared established scientific models of psychological well-being to a recent meditation-based framework for human flourishing [7]; and we addressed the need for studies of meditation-based interventions in older adults (see [32]).

The trial also has important limitations. The generalisability of our findings to other populations of older adults is reduced because our sample consisted of well-educated and largely white participants. Further, we did not include a passive control group to assess fluctuations in wellbeing independent of the interventions. Importantly, no self-report measures that specifically reflect the dimensions of Dahl et al.’s training-based framework for well-being [7] have been developed. Therefore, we utilised previously developed composite scores of meditation-related capacities that were based on self-report measures of trait-like individual differences [15]. These trait-level scales may be suboptimal for capturing the process-level aspects of meditation-related dimensions of psychological well-being.

Supporting information

S1 File. Contains supporting tables.

(PDF)

Acknowledgments

The Medit-Ageing Research Group includes: Claire André, Nicholas Ashton, Florence Allais, Julien Asselineau, Eider Arenaza-Urquijo, Romain Bachelet, Martine Batchelor, Axel Beaugonin, Viviane Belleoud, Clara Benson, Beatriz Bosch, Maelle Botton, Maria Pilar Casanova, Pierre Champetier, Anne Chocat, Nina Coll, Sophie Dautricourt, Pascal Delamillieure, Vincent De La Sayette, Marion Delarue, Harriet Demnitz-King, Titi Dolma, Stéphanie Egret, Francesca Felisatti, Eglantine Ferrand-Devouges, Eric Frison, Francis Gheysen, Karine Goldet, Julie Gonneaud, Abdul Hye, Agathe Joret Philippe, Elizabeth Kuhn, Brigitte Landeau, Gwendoline Ledu, Valérie Lefranc, Maria Leon, Dix Meiberth, Florence Mezenge, Ester Milz, Inès Moulinet, Hendrik Mueller, Theresa Mueller, Valentin Ourry, Cassandre Palix, Léo Paly, Géraldine Poisnel, Anne Quillard, Alfredo Ramirez, Géraldine Rauchs, Florence Requier, Leslie Reyrolle, Ana Salinero, Eric Salmon, Lena Sannemann, Yamna Satgunasingam, Christine Schwimmer, Hilde Steinhauser, Edelweiss Touron, Denis Vivien, Patrik Vuilleumier, Cédrick Wallet, Tim Whitfield, and Janet Wingrove. Many people helped in implementing these projects. The authors would like to thank all the contributors listed in the Medit-Ageing Research Group as well as Rhonda Smith, Charlotte Reid, the sponsor (Pôle de Recherche Clinique at Inserm), Inserm Transfert (Delphine Smagghe), and the participants in the Medit-Ageing project. Please address any correspondence relating to the Medit-Ageing Research Group to the project lead Gaël Chételat (chetelat@cyceron.fr).

Data Availability

The data underlying this report are made available on request following approval by the executive committee and a formal data sharing agreement (https://silversantestudy.eu/2020/09/25/data-sharing). The Material can be mobilized, under the conditions and modalities defined in the Medit-Ageing Charter by any research team belonging to an Academic institution, for carrying out a scientific research project relating to the scientific theme of mental health and well-being in older people. The Material may also be mobilized by non-academic third parties, under conditions, in particular financial, which will be established by separate agreement between Inserm and by the said third party. Data sharing policies described in the Medit-Ageing charter are in compliance with our ethics approval and guidelines from our funding body. Data contain potentially identifying or sensitive patient information. To request data, please contact the data access committee via the official project website (https://silversantestudy.eu/2020/09/25/data-sharing).

Funding Statement

The SCD-Well Randomised Controlled Trial is part of the Medit-Ageing project funded through the European Union in Horizon 2020 programme related to the call PHC22 “Promoting mental well-being in the ageing population” and under grant agreement No667696. FC was supported by Fonds National de la Recherche Scientifique (FRSFNRS, Belgium). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020. Mar;19(3):271–8. doi: 10.1016/S1474-4422(19)30368-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014. Dec;130(6):439–51. doi: 10.1111/acps.12336 [DOI] [PubMed] [Google Scholar]
  • 3.Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet Lond Engl. 2020;396(10248):413–46. doi: 10.1016/S0140-6736(20)30367-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Metternich B, Kosch D, Kriston L, Härter M, Hüll M. The Effects of Nonpharmacological Interventions on Subjective Memory Complaints: A Systematic Review and Meta-Analysis. Psychother Psychosom. 2010;79(1):6–19. doi: 10.1159/000254901 [DOI] [PubMed] [Google Scholar]
  • 5.Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, et al. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017;13(3):296–311. doi: 10.1016/j.jalz.2016.09.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bhome R, Berry AJ, Huntley JD, Howard RJ. Interventions for subjective cognitive decline: systematic review and meta-analysis. BMJ Open. 2018. Jul;8(7):e021610. doi: 10.1136/bmjopen-2018-021610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Dahl CJ, Wilson-Mendenhall CD, Davidson RJ. The plasticity of well-being: A training-based framework for the cultivation of human flourishing. Proc Natl Acad Sci. 2020. Dec 22;117(51):32197–206. doi: 10.1073/pnas.2014859117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Gu J, Strauss C, Bond R, Cavanagh K. How do mindfulness-based cognitive therapy and mindfulness-based stress reduction improve mental health and wellbeing? A systematic review and meta-analysis of mediation studies. Clin Psychol Rev. 2015. Apr 1;37:1–12. doi: 10.1016/j.cpr.2015.01.006 [DOI] [PubMed] [Google Scholar]
  • 9.Marchant NL, Barnhofer T, Coueron R, Wirth M, Lutz A, Arenaza-Urquijo EM, et al. Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. Psychother Psychosom. 2021. Apr 19;1–10. doi: 10.1159/000515669 [DOI] [PubMed] [Google Scholar]
  • 10.Smart CM, Segalowitz SJ, Mulligan BP, Koudys J, Gawryluk JR. Mindfulness Training for Older Adults with Subjective Cognitive Decline: Results from a Pilot Randomized Controlled Trial. J Alzheimers Dis. 2016. Jan 1;52(2):757–74. doi: 10.3233/JAD-150992 [DOI] [PubMed] [Google Scholar]
  • 11.Ryff CD. Psychological Well-Being Revisited: Advances in the Science and Practice of Eudaimonia. Psychother Psychosom. 2014;83(1):10–28. doi: 10.1159/000353263 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ryff CD. Happiness is everything, or is it? Explorations on the meaning of psychological well-being. J Pers Soc Psychol. 1989;57(6):1069–81. [Google Scholar]
  • 13.The Whoqol Group. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. Psychol Med. 1998. May;28(3):551–8. [DOI] [PubMed] [Google Scholar]
  • 14.Ryff CD, Lee C, Keyes M. The structure of psychological well-being revisited. In: Journal of Personality & Social Psychology. 1995. p. 719–27. doi: 10.1037//0022-3514.69.4.719 [DOI] [PubMed] [Google Scholar]
  • 15.Schlosser M, Barnhofer T, Requier F, Deza-Araujo YI, Abdoun O, Marchant NL, et al. Measuring Psychological Mechanisms in Meditation Practice: Using a Phenomenologically Grounded Classification System to Develop Theory-Based Composite Scores. Mindfulness. 2022. Mar 1;13(3):600–14. [Google Scholar]
  • 16.Dahl CJ, Lutz A, Davidson RJ. Reconstructing and deconstructing the self: cognitive mechanisms in meditation practice. Trends Cogn Sci. 2015. Sep 1;19(9):515–23. doi: 10.1016/j.tics.2015.07.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lutz A, Chételat G, Collette F, Klimecki OM, Marchant NL, Gonneaud J. The protective effect of mindfulness and compassion meditation practices on ageing: Hypotheses, models and experimental implementation. Ageing Res Rev. 2021. Dec 1;72:101495. doi: 10.1016/j.arr.2021.101495 [DOI] [PubMed] [Google Scholar]
  • 18.Marchant NL, Barnhofer T, Klimecki OM, Poisnel G, Lutz A, Arenaza‐Urquijo E, et al. The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). Alzheimers Dement Transl Res Clin Interv. 2018;4(1):737–45. doi: 10.1016/j.trci.2018.10.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Jessen F, Amariglio RE, Boxtel M van, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–52. doi: 10.1016/j.jalz.2014.01.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lorig K, Holman H, Sobel D, Laurent D, Gonzalez V, Minor M. Living a Healthy Life with Chronic Conditions: For Ongoing Physical and Mental Health Conditions. 4th ed. Bull Publishing Company; 2012. [Google Scholar]
  • 21.Mehling WE, Price C, Daubenmier JJ, Acree M, Bartmess E, Stewart A. The Multidimensional Assessment of Interoceptive Awareness (MAIA). PLOS ONE. 2012. Nov 1;7(11):e48230. doi: 10.1371/journal.pone.0048230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using Self-Report Assessment Methods to Explore Facets of Mindfulness. Assessment. 2006. Mar 1;13(1):27–45. doi: 10.1177/1073191105283504 [DOI] [PubMed] [Google Scholar]
  • 23.Sprecher S, Fehr B. Compassionate love for close others and humanity. J Soc Pers Relatsh. 2005. Oct 1;22(5):629–51. [Google Scholar]
  • 24.Schlosser M, Pfaff NG, Schweinberger SR, Marchant NL, Klimecki OM. The psychometric properties of the compassionate love scale and the validation of the English and German 7-item compassion for others scale (COS-7). Curr Psychol. 2021;42(1):579–91. [Google Scholar]
  • 25.Forman EM, Herbert JD, Juarascio AS, Yeomans PD, Zebell JA, Goetter EM, et al. The Drexel defusion scale: A new measure of experiential distancing. J Context Behav Sci. 2012. Dec 10;1(1):55–65. [Google Scholar]
  • 26.Chen KW, Berger CC, Manheimer E, Forde D, Magidson J, Dachman L, et al. Meditative therapies for reducing anxiety: a systematic review and meta-analysis of randomized controlled trials. Depress Anxiety. 2012. Jul;29(7):545–62. doi: 10.1002/da.21964 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.John OP, Srivastava S. The Big Five Trait taxonomy: History, measurement, and theoretical perspectives. In: Handbook of personality: Theory and research, 2nd ed. New York, NY, US: Guilford Press; 1999. p. 102–38. [Google Scholar]
  • 28.Chételat G, Lutz A, Arenaza-Urquijo E, Collette F, Klimecki O, Marchant N. Why could meditation practice help promote mental health and well-being in aging? Alzheimers Res Ther. 2018. Jun 22;10(1):57. doi: 10.1186/s13195-018-0388-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Goldberg SB, Imhoff-Smith T, Bolt DM, Wilson-Mendenhall CD, Dahl CJ, Davidson RJ, et al. Testing the Efficacy of a Multicomponent, Self-Guided, Smartphone-Based Meditation App: Three-Armed Randomized Controlled Trial. JMIR Ment Health. 2020. Nov 27;7(11):e23825. doi: 10.2196/23825 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hirshberg MJ, Frye C, Dahl CJ, Riordan KM, Vack NJ, Sachs J, et al. A randomized controlled trial of a smartphone-based well-being training in public school system employees during the COVID-19 pandemic. J Educ Psychol. 2022;No Pagination Specified-No Pagination Specified. doi: 10.1037/edu0000739 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Poisnel G, Arenaza-Urquijo E, Collette F, Klimecki OM, Marchant NL, Wirth M, et al. The Age-Well randomized controlled trial of the Medit-Ageing European project: Effect of meditation or foreign language training on brain and mental health in older adults. Alzheimers Dement Transl Res Clin Interv. 2018. Jan 1;4:714–23. doi: 10.1016/j.trci.2018.10.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Goldberg SB, Riordan KM, Sun S, Davidson RJ. The Empirical Status of Mindfulness-Based Interventions: A Systematic Review of 44 Meta-Analyses of Randomized Controlled Trials. Perspect Psychol Sci. 2022. Jan 1;17(1):108–30. doi: 10.1177/1745691620968771 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Rosenkranz MA, Dunne JD, Davidson RJ. The next generation of mindfulness-based intervention research: what have we learned and where are we headed? Curr Opin Psychol. 2019. Aug;28:179–83. doi: 10.1016/j.copsyc.2018.12.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Van Dam NT, van Vugt MK, Vago DR, Schmalzl L, Saron CD, Olendzki A, et al. Mind the Hype: A Critical Evaluation and Prescriptive Agenda for Research on Mindfulness and Meditation. Perspect Psychol Sci. 2018. Jan 1;13(1):36–61. doi: 10.1177/1745691617709589 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Marcelo Marcos Piva Demarzo

24 Aug 2023

PONE-D-23-18446Effects of a mindfulness-based intervention and a health self-management programme on psychological well-being in older adults with subjective cognitive decline: Secondary analyses from the SCD-Well randomised clinical trialPLOS ONE

Dear Dr. Lutz,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:Dear Authors,

Please, respond to reviewers recommendations in order to submit the new version of the paper (incl. the responses to reviewers).

Best regards

Editor

==============================

Please submit your revised manuscript by Oct 08 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Marcelo Marcos Piva Demarzo, MD, PhD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Competing Interests section:

“GC has received research support from the EU’s Horizon 2020 research and innovation programme (grant agreement number 667696), Inserm, Fondation d’entreprise MMA des Entrepreneurs du Futur, Fondation Alzheimer, Programme Hospitalier de Recherche Clinique, Région Normandie, Association France Alzheimer et maladies apparentées and Fondation Vaincre Alzheimer (all to Inserm), and personal fees from Fondation d’entreprise MMA des Entrepreneurs du Futur. All other authors have declared that no competing interests exist.”

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

3. One of the noted authors is a group or consortium [The Medit-Ageing Research Group]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

Additional Editor Comments:

Dear Authors,

Please, respond to reviewers recommendations in order to submit the new version of the paper (incl. the responses to reviewers).

Best regards

Editor

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Important note: This review pertains only to ‘statistical aspects’ of the study and so ‘clinical aspects’ [like medical importance, relevance of the study, ‘clinical significance and implication(s)’ of the whole study, etc.] are to be evaluated [should be assessed] separately/independently. Further please note that any ‘statistical review’ is generally done under the assumption that (such) study specific methodological [as well as execution] issues are perfectly taken care of by the investigator(s). This review is not an exception to that and so does not cover clinical aspects {however, seldom comments are made only if those issues are intimately / scientifically related & intermingle with ‘statistical aspects’ of the study}. Agreed that ‘statistical methods’ are used as just tools here, however, they are vital part of methodology [and so should be given due importance]. I look at the manuscript in/with statistical view point, other reviewer(s) look(s) at it with different angle so that in totality the review is very comprehensive. However, there should be efforts from authors side to improve (may be by taking clues from reviewer’s comments). Therefore, please do not limit the revision only (with respect) to comments made here.

COMMENTS: Although this manuscript is well drafted and the study seems to have enough potential (is on very important/useful topic), I have few doubts/observations/concerns (different opinion) which are little serious and are given below:

In ‘Methods’ section it is stated that ‘Detailed information about the recruitment procedures, eligibility criteria, design of the interventions, and assessments can be found in the trial protocol’ and quoted reference (18). But reference 18 seems to be a report of the trial and not the ‘PROTOCOL’. It is stated there that ‘The treatment is based on a published manual [24], with every session of the program covering different subjects, including self-management’ which indicates that some sort of / some amount of ‘self-management’ component was there. Then is it not necessary to clarify regarding the overlap? It is well-known (NET/WWW search) that “Secondary analysis refers to the use of existing research data to find answer to a question that was different from the original work” then is this study can be called as ‘Secondary analyses’ [as mentioned in title]? I am sure that the authors are aware of limitations/disadvantages of Secondary Data Analysis, however, I request authors to kindly read the following pasted from one famous standard textbook on ‘Medical Research Methodology’:

Since the researcher did not collect the data, he or she has no control over what is contained in the data set. Often times this can limit the analysis or alter the original questions the researcher sought out to answer.

You may consider to change the ‘title’ (only if convinienced). The present study (manuscript) seems to be a report of component/part [hitherto unpublished in this form] of the same (the SCD-Well randomised controlled trial of the European) trial. Further, please note that though application of ‘Mixed effects models’ here is perfectly alright, they are [any regression techniques for that matter] are not basically/originally developed for any sort of [between or within group(s)] comparison(s). In ‘Methods’ section you stated that “Mixed effects models were used to assess between- and within-group differences in change”. Head-to-head comparison is expected, as this is [through ‘Mixed effects models’] an indirect/secondary/by-product testing, in my opinion. Application of ‘Mixed effects models’ could definitely be (useful) addition (I am sure). Even if ultimate results are same, one should follow a correct way (I think).

Note that, though the measures/tools used are appropriate {example: 42-item Psychological Well-being Scale (PWBS), Quality of Life Assessment (by WHOQOL-BREF), four self-report measures (displayed in Table 2) - The Multidimensional Assessment of Interoceptive Awareness (MAIA) questionnaire and the 39-item Five Facet Mindfulness Questionnaire (FFMQ-39), etc.}, most of them are likely to yield data that are in [at the most] ‘ordinal’ level of measurement [and not in ratio level of measurement for sure {as the score two times higher does not indicate presence of that parameter/phenomenon as double (for example, a Visual Analogue Scales VAS score or say ‘depression’ score)}]. Then application of suitable non-parametric (or distribution free) test(s) is/are indicated/advisable [even if distribution may be ‘Gaussian’ (also called ‘normal’)]. Agreed that there is/are no non-parametric test(s)/technique(s) available to be used as alternative in all situation(s), but should be used whenever/wherever they are available. Therefore, in short use suitable non-parametric test(s)/technique(s) while dealing with data that are in ‘ordinal’ level of measurement even if [despite that] the distribution may be ‘Gaussian’. Testing ‘normality’ in sample [by using any normality test(s)} is not required/desired while dealing with data that are in ‘ordinal’ level of measurement [as most of the normality tests are not valid for ‘ordinal’ data].

It may also (as often said) please be noted, [as you stated: Each dimension is measured by a 7-item subscale using a 7-point Likert scale ranging from 1 (strongly agree) to 7 (strongly disagree). After reverse scoring 21 items, subscale scores were derived by averaging their respective item scores; a total score was derived by averaging all items] that whenever response options ranged from 1 (=strongly agree) to 7 (=strongly disagree) {or from 1=very bad to 3=neither good nor bad to 5=very good), while using a ‘Likert’ scale responses, recoding [like strongly disagree=-2, disagree=-1, neutral=0, agree=1, strongly agree=2] may yield correct and meaningful ‘arithmetic mean’ which is useful not only for comparison but has absolute meaning, in my opinion. Application of any statistical test(s) assume that meaning of entity used (mean, SD, etc) has a particular meaning. Though ‘α’ [alpha] or most other measures of reliability/correlation will remain same, however, use of non-parametric methods should/may be preferred while dealing with data yielded by any questionnaire/score.

At the end of ‘Introduction’ section it is said that “We hypothesised that both interventions would improve well-being but that CMBAS would be superior to HSMP”, then what about the principle of ‘equipoise’ [equipoise means that there is genuine uncertainty in the expert medical community over whether a treatment will be beneficial. An ethical dilemma arises in a clinical trial when the investigator(s) begin to believe that the treatment or intervention administered in one arm of the trial is significantly outperforming the other arms.]? Again, as often said, some sort of ‘bias’ is (are) likely be introduced/present when the principle of ‘equipoise’ is not observed/followed.

In ‘Statistical analyses -Sample size’ section is it adequate to say “Sample size calculations in SCD-Well were based on the expected effect size ….’? Do not it necessary to mention ‘what that expected effect size’ you are referring to?

Except these minor points, the article is acceptable [drafting is excellent]. Nevertheless, mind you that as pointed out in ‘important note’ above “This review pertains only to ‘statistical aspects’ of the study and so ‘clinical aspects’ should be assessed separately/independently. ‘Minor Revision’ is recommended.

Reviewer #2: This is a well-written manuscript reporting the findings of an RCT comparing the effects of a mindfulness-based intervention vs. a health education program on wellbeing-related outcomes in participants with subjective cognitive decline. I will defer to the statistical reviewer regarding the appropriateness and rigor of the statistical analysis. While the data is not being made fully available without restriction, it appears that the authors have addressed the issue satisfactorily. The following are items I believe still need to be addressed.

1. It appears that some items recommended by CONSORT were not reported. I suggest consulting the CONSORT NPT extension and addressing any items that are currently lacking. I believe PLOS ONE also requires a completed CONSORT checklist and flow diagram as part of the submission for manuscripts reporting results of clinical trials.

2. The citation style is inconsistent and should be corrected.

3. In describing the HSMP intervention a published manual is mentioned. A citation to the manual should be provided.

4. In the comparative analyses section a pre-registered statistical analysis plan is mentioned. If this plan is available, information on where to access it should be provided.

5. Session attendance is included as a potential moderator variable, yet home practice did not seem to be included. Given that the majority of the time spent doing the intervention appears to be during home practice, I believe it warrants attention. On a related note, information on adherence (e.g., number of sessions attended, number/hours of home practice completed) would also be useful.

6. Looking at table 2, in general it appears there was a drop off in the number of participants from V1 to V2 for both groups, then V3 rebounded a bit for the HSMP group but not the CMBAS group. Was there some reason that might explain this difference?

7. When discussing generalizability of the findings, it is mentioned that the participants were largely white. The data supporting this should be provided in Table 1.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: renamed_e64c2.docx

Decision Letter 1

Marcelo Marcos Piva Demarzo

10 Oct 2023

PONE-D-23-18446R1Effects of a mindfulness-based intervention and a health self-management programme on psychological well-being in older adults with subjective cognitive decline: Secondary analyses from the SCD-Well randomised clinical trialPLOS ONE

Dear Dr. Lutz,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 24 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Marcelo Marcos Piva Demarzo, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Dear Authors,

Thank you for sending the revised manuscript, which partially met the quality criteria for final acceptance.

For final acceptance of the manuscript to occur, please pay attention to the following minor points (raised by our reviewers):

- In the introduction, the authors indicated “Although the condition could be an indication of prodromal Alzheimer’s disease (AD), which is the most common form of dementia (3), SCD has also been related to other factors (e.g., physical and mental illness, sleep disturbances, personality traits, effects of drugs).” It could be that the lack of effect is due to these other factors, especially when there is no consensus of what constitutes an SCD. Please, address this point in the discussion;

- Note that was suggested by one reviewer that (refer to previous item 4) “Head-to-head comparison” could be ideally used instead of ‘Mixed effects models’. Please, answer this comment in more details, and, if necessary, point this as a limitation in the discussion section.

Best regards

Editor

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: COMMENTS: All the comments are answered and so I recommend the acceptance because the manuscript has now achieved the acceptable level.

[However, please note that I suggested (refer to item 4) “Head-to-head comparison” {and said comparative inference drawn through ‘Mixed effects models’ done here is an indirect/secondary/by-product testing, in my opinion. Application of ‘Mixed effects models’ could definitely be (useful) addition (I am sure). Even if ultimate results are same, one should follow a correct way (I think)]. In response it is said that “We agree with the reviewer that the mixed effects models we have employed are an appropriate and effective method to answer our research questions” and there is NO mention of “Head-to-head comparison”.]

Reviewer #3: In the introduction, the authors indicated “Although the condition could

be an indication of prodromal Alzheimer’s disease (AD), which is the most common form of

dementia (3), SCD has also been related to other factors (e.g., physical and mental illness,

sleep disturbances, personality traits, effects of drugs).” It could be that the lack of effect is due to these other factors, especially when there is no consensus of what constitutes an SCD. It will be prudent to address this issue in the discussion.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dr. Sanjeev Sarmukaddam

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 2

Marcelo Marcos Piva Demarzo

16 Nov 2023

Effects of a mindfulness-based intervention and a health self-management programme on psychological well-being in older adults with subjective cognitive decline: Secondary analyses from the SCD-Well randomised clinical trial

PONE-D-23-18446R2

Dear Dr. Marchant,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Marcelo Marcos Piva Demarzo, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Contains supporting tables.

    (PDF)

    Attachment

    Submitted filename: Response Letter to Reviewers.docx

    Attachment

    Submitted filename: renamed_e64c2.docx

    Attachment

    Submitted filename: Response Letter to Reviewers.docx

    Attachment

    Submitted filename: Response Letter to Reviewers.docx

    Data Availability Statement

    The data underlying this report are made available on request following approval by the executive committee and a formal data sharing agreement (https://silversantestudy.eu/2020/09/25/data-sharing). The Material can be mobilized, under the conditions and modalities defined in the Medit-Ageing Charter by any research team belonging to an Academic institution, for carrying out a scientific research project relating to the scientific theme of mental health and well-being in older people. The Material may also be mobilized by non-academic third parties, under conditions, in particular financial, which will be established by separate agreement between Inserm and by the said third party. Data sharing policies described in the Medit-Ageing charter are in compliance with our ethics approval and guidelines from our funding body. Data contain potentially identifying or sensitive patient information. To request data, please contact the data access committee via the official project website (https://silversantestudy.eu/2020/09/25/data-sharing).


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES